Pharmaceutical scientists, clinicians, nurses and pharmacists from the National University of Singapore (NUS) and National University Hospital (NUH) have shown that a reduced dose of abiraterone acetate is potentially as effective and safe as the standard regimen for prostate cancer patients.
This article was originally published on MedicalXpress.com